SAN DIEGO, Nov. 25, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that Daniel Faga, president and chief executive officer of Anaptys, and/or other members of its executive leadership team, are scheduled to participate in multiple upcoming investor conferences: Piper Sandler 37th Annual Healthcare Conference, New York, NY Format – Fireside chat and 1x1 investor meetingsDate and Time – ...

SAN DIEGO, Nov. 21, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (NASDAQ:ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that its Board of Directors has authorized an amended Stock Repurchase Plan under which the Company may repurchase up to $100.0 million of the Company's outstanding common stock, par value $0.001 per share. This amendment is in addition to the $6.4 million that remained as of Nov. 20, 2025 under the current $75.0 million ...

Core Viewpoint - AnaptysBio, Inc. has authorized an amended Stock Repurchase Plan allowing for the repurchase of up to $100 million of its common stock, in addition to the remaining $6.4 million from the previous plan [1][2] Group 1: Stock Repurchase Plan - The amended Stock Repurchase Plan allows AnaptysBio to repurchase up to $100 million of its outstanding common stock, with $6.4 million remaining from the previous $75 million plan [1] - As of November 20, 2025, AnaptysBio has repurchased a total of 3,443,188 shares, representing 11.2% of shares outstanding before the initiation of the repurchase plan [1] - The new plan will expire on March 31, 2026, and the timing and number of shares repurchased will depend on market conditions and other factors [3] Group 2: Financial Position - AnaptysBio anticipates ending 2025 with approximately $300 million in cash, cash equivalents, and investments, which includes a one-time $75 million commercial sales milestone expected in Q4 2025 from GSK [2] Group 3: Company Overview - AnaptysBio is a clinical-stage biotechnology company focused on innovative immunology therapeutics for autoimmune and inflammatory diseases, with a pipeline that includes several candidates in various stages of clinical trials [4] - The company plans to separate its biopharma operations from its royalty assets by the end of 2026, allowing investors to align their investment strategies with each entity's objectives [5]

Core Viewpoint - AnaptysBio has filed a Verified Complaint against Tesaro and GSK, alleging material breaches of their Collaboration Agreement and seeking legal remedies [1][2]. Group 1: Legal Disputes - Anaptys claims that Tesaro breached the Collaboration Agreement by participating in clinical trials with competing PD-1 antagonists and failing to use reasonable efforts to maximize commercial returns for Jemperli [2]. - Tesaro has initiated its own lawsuit against Anaptys, alleging that Anaptys improperly claimed breaches of the Collaboration Agreement [4]. - The parties are seeking an expedited trial schedule in Delaware Chancery Court, with a trial expected in July 2026 [5]. Group 2: Financial Implications - Anaptys is entitled to royalties from Jemperli sales, structured as 8% for net sales below $1 billion, 12% for sales between $1 billion and $1.5 billion, 20% for sales between $1.5 billion and $2.5 billion, and 25% for sales above $2.5 billion [7]. - A one-time $75 million commercial sales milestone is anticipated once Jemperli achieves $1 billion in worldwide net sales [7]. - Anaptys estimates that Sagard will accrue $250 million in royalties and sales milestones through the end of 2025, with full paydown expected between Q2 2027 and Q2 2028 [9]. Group 3: Background of the Collaboration - The Collaboration Agreement was established in March 2014, allowing Tesaro to develop Jemperli for various solid tumor indications [6]. - Anaptys previously filed a complaint against GSK in 2020 regarding breaches related to GSK's clinical trial of Zejula, which resulted in a settlement that included cash payments and increased royalties on Jemperli [3]. Group 4: Company Overview - AnaptysBio is a clinical-stage biotechnology company focused on innovative immunology therapeutics for autoimmune and inflammatory diseases, with a pipeline that includes multiple therapeutic candidates [10]. - The company plans to separate its biopharma operations from its royalty assets by the end of 2026 to better align with investor interests [11].

Core Viewpoint - AnaptysBio has filed a Verified Complaint against Tesaro and GSK, alleging material breaches of their Collaboration Agreement and seeking legal remedies [1][2]. Group 1: Legal Dispute - The Complaint asserts that Tesaro breached the Collaboration Agreement by engaging in clinical trials with competing PD-1 antagonists, including Keytruda, and failed to use reasonable efforts to maximize commercial returns for Jemperli [2]. - Anaptys previously filed a complaint against GSK in 2020 for similar breaches related to GSK's clinical trial of Zejula in combination with Keytruda, which resulted in a settlement that included cash payments and increased royalties on Jemperli [3]. - Tesaro has initiated its own lawsuit against Anaptys, claiming that Anaptys has breached the Collaboration Agreement, which Anaptys contends is without merit [4]. Group 2: Collaboration Agreement Details - The Collaboration Agreement, established in March 2014, involves Tesaro developing Jemperli for various solid tumor indications [6]. - Anaptys is entitled to royalties from Jemperli sales, structured as 8% for net sales below $1 billion, 12% for sales between $1 billion and $1.5 billion, 20% for sales between $1.5 billion and $2.5 billion, and 25% for sales above $2.5 billion [7]. - A one-time $75 million commercial sales milestone is anticipated once Jemperli achieves $1 billion in worldwide net sales [7]. Group 3: Financial Implications - The royalty term under the Collaboration Agreement extends until the expiration of composition of matter coverage, which is set to expire in 2035 in the U.S. and 2036 in the EU [8]. - Anaptys estimates that Sagard will have accrued $250 million in royalties and sales milestones through the end of 2025, with full paydown of $600 million expected between Q2 2027 and Q2 2028 [9]. Group 4: Future Developments - The parties have agreed to an expedited schedule with the Delaware Chancery Court, with a trial anticipated in July 2026 [5]. - Milestone and royalty payment obligations to Anaptys will continue during the legal proceedings [5].

Core Insights - The article highlights the services offered by Biotech Analysis Central, which provides in-depth analysis of pharmaceutical companies and investment opportunities in the biotech sector [1][2]. Group 1: Company Overview - Biotech Analysis Central is a platform that includes a library of over 600 biotech investing articles and a model portfolio featuring more than 10 small and mid-cap stocks, each with detailed analysis [2]. - The service is available for $49 per month, with a discounted annual plan at $399, representing a 33.50% savings for subscribers [1]. Group 2: Analyst Background - The founder, Terry Chrisomalis, is a private investor with extensive experience in the biotech sector, leveraging an Applied Science background to create long-term value in healthcare investments [2].

Summary of AnaptysBio Conference Call Company Overview - **Company**: AnaptysBio - **Industry**: Biotechnology Key Points and Arguments 1. Business Split Announcement - AnaptysBio plans to split into two entities: a royalty-focused company and a biopharma company, aimed at enhancing shareholder value and focusing on distinct investor interests [6][9][10] 2. Rosnilimab Development - Rosnilimab, a selective T cell depleter, completed a phase 2b trial in arthritis with 424 patients, showing significant efficacy and safety, with statistically significant results at week 12 [2][3] - The drug demonstrated low disease activity and remission rates that improved over six months and persisted for nine months post-treatment [2][3][18] 3. ANB033 Development - ANB033, a CD122 receptor antagonist, is currently in a phase 1b trial for celiac disease, with plans to announce a second indication in 2026 [4][30] - The trial design includes two cohorts: one undergoing a gluten challenge and another with significant mucosal damage not receiving gluten [28][29] 4. Jemperli Royalty Stream - AnaptysBio has a significant royalty stream from Jemperli, projected to reach a $1.5 billion run rate by year-end, with potential royalties of $390 million when GSK achieves peak sales of over $2.7 billion [4][5][11] - Jemperli is positioned as a market leader in frontline endometrial cancer, with expectations for substantial growth [7][12] 5. Market Expectations and Consensus - There is a notable discrepancy between GSK's sales guidance for Jemperli and Wall Street consensus, with GSK projecting far greater sales than the consensus estimate of $1.9 billion [10][11] - AnaptysBio believes the royalty from Jemperli alone is worth significantly more than its current market cap [12] 6. Future Plans and Funding - AnaptysBio plans to meet with the FDA to discuss the phase 3 program for Rosnilimab and explore various funding options for the RA program [19][20] - The company is considering strategic collaborations to support the development of its pipeline [20] 7. Safety and Efficacy in Trials - The safety profile of Rosnilimab is favorable, with less than 2% of patients discontinuing due to adverse events [18][23] - The company remains confident in the RA program despite a recent setback in ulcerative colitis trials, citing strong translational data supporting the drug's mechanism of action [21][22][24] 8. Market Opportunity in Arthritis - There is a significant market opportunity in the arthritis space, with over 500,000 patients in the U.S. on biologics and many progressing beyond TNFs [15][16] - Rosnilimab is expected to perform well in patients who have previously undergone multiple therapies [16][17] 9. Upcoming Data and Milestones - Data from the ANB033 trial is expected next year, which will provide insights into its efficacy and potential for future development [30] Additional Important Information - The company is well-capitalized, anticipating over $300 million in cash by year-end, including milestone payments from GSK [5]

Core Insights - AnaptysBio Inc. announced data from the Phase 2 trial of rosnilimab for moderate-to-severe ulcerative colitis, indicating that the drug did not meet its primary or key secondary endpoints [2][5]. Trial Results - Rosnilimab was found to be safe and well-tolerated, but it performed no better than placebo at Week 12, with clinical remission rates of 7% for patients receiving 400mg Q4W and 800mg Q2W, compared to 5% and 4% for endoscopic remission [2][5]. - The placebo rates in the trial were within expected historical ranges [2]. - Preliminary data suggested an increase in remission rates between Week 12 and Week 24, but these rates did not meet the six-month target product profile [5]. Financial Implications - The company will discontinue the ulcerative colitis trial, resulting in at least $10 million in savings [3]. Future Plans - AnaptysBio remains optimistic about the potential of rosnilimab in rheumatoid arthritis (RA) and plans to provide an update in H1 2026, including funding strategies that do not dilute royalties [4]. - The company is also conducting a Phase 1b study for ANB033 for celiac disease and plans to announce another Phase 1b study in a different inflammatory disease in 2026 [7]. Market Reaction - Following the announcement, AnaptysBio shares fell by 13.63%, trading at $34.24 [8]. Strategic Moves - AnaptysBio reiterated its intention to separate biopharma assets from substantial royalty assets in 2026, including expected royalties of over $390 million per year from Jemperli at GSK's peak sales guidance of over $2.7 billion [8].

Core Insights - AnaptysBio announced that rosnilimab was safe and well tolerated but failed to meet primary and key secondary endpoints in a Phase 2 trial for moderate-to-severe ulcerative colitis, leading to the discontinuation of the trial and an estimated savings of at least $10 million [1][6][9] Group 1: Trial Results - The Phase 2 trial enrolled 136 patients with a baseline mean modified Mayo Score (mMS) of 6.7, who had inadequate responses to prior therapies [2][3] - At Week 12, clinical remission was achieved by 7% of patients receiving rosnilimab, compared to 5% and 4% for endoscopic remission [3][4] - Blood biomarker data indicated ~90% depletion of pathogenic T cells at Week 12, consistent with previous studies [4][6] Group 2: Future Plans - The company remains optimistic about advancing rosnilimab in rheumatoid arthritis (RA) and plans to provide updates in H1 2026, with funding expected from strategic sources without diluting royalties [2][6] - AnaptysBio intends to separate its biopharma assets from its royalty assets by 2026, which includes Jemperli royalties projected to exceed $390 million annually [2][11] Group 3: Safety Profile - Rosnilimab demonstrated a favorable safety profile, with adverse events primarily mild to moderate, including nasopharyngitis and dizziness [7][13] - No serious adverse events or malignancies were reported, and the ongoing safety profile remains consistent with previous studies [8][13]

Company Overview - AnaptysBio, Inc. is a clinical-stage biotechnology company focused on innovative immunology therapeutics for autoimmune and inflammatory diseases [2] - The lead program, rosnilimab, has completed a Phase 2b trial for rheumatoid arthritis and is currently in a Phase 2 trial for ulcerative colitis [2] - The pipeline includes ANB033, a CD122 antagonist in a Phase 1b trial for celiac disease, and ANB101, a BDCA2 modulator in a Phase 1a trial [2] - Anaptys has out-licensed multiple therapeutic antibodies, including a PD-1 antagonist to GSK and an IL-36R antagonist to Vanda Pharmaceuticals [2] Upcoming Events - Daniel Faga, CEO, and other executives will participate in several investor conferences, including the TD Cowen Immunology & Inflammation Summit and the Jefferies Global Healthcare Conference [1] - Live webcasts of the events will be available on the investor section of the Anaptys website, with replays accessible for at least 30 days [1] Strategic Developments - Anaptys plans to separate its biopharma operations from its royalty assets by the end of 2026, allowing investors to align their investment strategies with the distinct opportunities of each entity [3]